首页 | 本学科首页   官方微博 | 高级检索  
检索        

胱抑素C、血浆尾加压素Ⅱ在失代偿期肝硬化合并肝肾综合征患者中的诊断价值
引用本文:郑晓丽,汪良芝,贺建华,向兴朝,周翔禹.胱抑素C、血浆尾加压素Ⅱ在失代偿期肝硬化合并肝肾综合征患者中的诊断价值[J].临床肝胆病杂志,2013,29(8):627-630.
作者姓名:郑晓丽  汪良芝  贺建华  向兴朝  周翔禹
作者单位:郑晓丽 (恩施州中心医院消化内科,湖北恩施,445000); 汪良芝 (常州市第一人民医院消化内科,江苏常州,213003); 贺建华 (恩施州中心医院消化内科,湖北恩施,445000); 向兴朝 (恩施州中心医院消化内科,湖北恩施,445000); 周翔禹 (恩施州中心医院消化内科,湖北恩施,445000);
摘    要:目的探讨胱抑素C(CysC)、血浆尾加压素Ⅱ(uⅡ)在失代偿期肝硬化合并肝肾综合征(HRS)患者中的诊断价值。方法收集2011年2月-2011年11月于常州市第一人民医院消化内科住院的失代偿期肝硬化患者50例,计算其校正内生肌酐清除率(Ccr),并根据Ccr分为单纯肝硬化组、亚临床HRS组及HRS组,以15例健康体检者为对照组,检测ALT、AST、总胆汁酸(TBA)、Alb、血清肌酐(Scr)、CysC、uⅡ浓度,比较各组上述指标的差异,若数据成正态分布且方差齐,进行单因素方差分析(One-Way ANOVA),两组间比较采用t检验;否则,多组间进行非参数秩和检验(Kruskall-Wallis H test),两组间比较使用Mann-Whjtney U检验。相关分析采用Spearman相关检验。并通过绘制CysC、uⅡ浓度判断肝硬化合并亚临床HRS及HRS的ROC曲线,获得其曲线下面积(AUC)及最佳临界值。结果肝硬化病例组与正常对照组ALT、AST、TBA、Alb、Scr、Cysc、uⅡ比较差异有统计学意义。单纯肝硬化组、亚临床HRS组及HRS组CysC、uⅡ浓度均呈升高趋势,差异具有统计学意义(P〈0.05)。CysC和uⅡ判断亚临床HRS的AUC分别为0.91和0.867,其最佳临界值分别为1.40 mg/L、299.06 pg/ml。CysC和uⅡ判断HRS的AUC分别为0.942和0.901,其最佳临界值分别为2.22 mg/L、321pg/ml。结论 CysC、uⅡ浓度在患者血清肌酐正常时就出现升高改变,有助于早期发现亚临床HRS。CysC、uⅡ浓度对失代偿期肝硬化患者并发亚临床HRS及HRS有很好的判别价值。

关 键 词:半胱氨酸蛋白酶抑制剂  尿紧张素类  肝肾综合征  肝硬化  诊断

Diagnostic value of serum cystatin C and urotensin II for hepatorenal syndrome in patients with decompensated liver cirrhosis
Institution:ZHENG Xiaoli,WANG Liangzhi,HE Jianhua,et al.(Department of Gastroenterology,Central Hospital of Enshi Autonomous Prefecture,Enshi,Hubei 445000,China)
Abstract:Objective To evaluate the relation of serum cystatin C(CysC) and urotensin II(uII) levels with presence of hepatorenal syndrome in patients with decompensated liver cirrhosis to determine the diagnostic potential for these serum markers in order to facilitate early detection of hepatorenal syndrome at subclinical stages.Methods A total of 50 patients with decompensated liver cirrhosis were recruited for study and divided into three groups according to creatinine elimination rate(Ccr): simple liver cirrhosis,≥80 ml/min(n=22);subclinical hepatorenal syndrome,40≤Ccr80 ml/min(n=19);and hepatorenal syndrome,≤40 ml/min(n=9).Fifteen healthy individuals were recruited for use as controls.Fasting blood samples were collected from all cases and controls for measurements of alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bile acid(TBA),albumin(Alb),serum creatinine(Scr),CysC,and uII.For normally distributed data,single-factor analysis was carried out by One-Way ANOVA and pairwise comparisons were carried out by the Student′s t-test;for non-normally distributed data,the Kruskall-Wallis H test and Mann-Whitney U test were used,respectively.Correlation analysis was carried out with the Spearman′s rank correlation coefficient.Diagnostic accuracy was assessed by generating a receiver operating characteristic(ROC) curve and using the area under the curve(AUC) to select the optimal threshold for diagnosing subclinical hepatorenal syndrome and hepatorenal syndrome in patients with decompensated liver cirrhosis.Results Compared to the healthy controls,the cirrhosis cases had significantly higher levels of ALT,AST,TBA,ALB,Scr,CysC,and uII(all P0.05).However,among the cirrhotic patients,those with subclinical hepatorenal syndrome and hepatorenal syndrome had slightly,but significantly,higher levels of CysC and uII than the patients with simple cirrhosis(both P0.05).For subclinical hepatorenal syndrome,the AUCs of CysC and uII were 0.91 and 0.867 and the optimal thresholds were 1.40 mg/L and 299.06 pg/ml respectively.For hepatorenal syndrome,the AUCs of CysC and uII were 0.942 and 0.901 and the optimal thresholds were 2.22 mg/L and 321 pg/ml respectively.Conclusion Enhanced levels of serum CysC and uII can reflect hepatorenal damage in patients with decompensated liver cirrhosis,even when serum creatinine levels are within normal range,suggesting that these two serum markers may have diagnostic value for detecting subclinical hepatorenal syndrome and hepatorenal syndrome at early stages in this patient population.
Keywords:cysteine proteinase inhibitors  urotensins  hepatorenal syndrome  liver cirrhosis  diagnosis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号